![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Geodon, Zeldox, Zipwell, other |
AHFS/Drugs.com | Monograph |
MedlinePlus | a699062 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth, intramuscular injection (IM) |
Drug class | Atypical antipsychotic |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 60% (oral) [3] 100% (IM) |
Metabolism | Liver (aldehyde reductase) |
Elimination half-life | 7 to 10 hours [4] |
Excretion | Urine and feces |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.106.954 |
Chemical and physical data | |
Formula | C21H21ClN4OS |
Molar mass | 412.94 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Ziprasidone, sold under the brand name Geodon among others, is an atypical antipsychotic used to treat schizophrenia and bipolar disorder. [5] It may be used by mouth and by injection into a muscle (IM). [5] The IM form may be used for acute agitation in people with schizophrenia. [5]
Common side effects include dizziness, drowsiness, dry mouth, and twitches. [6] [7] Although it can also cause weight gain, the risk is much lower than for other atypical antipsychotics. [8] How it works is not entirely clear but is believed to involve effects on serotonin and dopamine in the brain. [5]
Ziprasidone was approved for medical use in the United States in 2001. [5] The pills are made up of the hydrochloride salt, ziprasidone hydrochloride. The intramuscular form is the mesylate, ziprasidone mesylate trihydrate, and is provided as a lyophilized powder. In 2020, it was the 282nd most commonly prescribed medication in the United States, with more than 1 million prescriptions. [9] [10]
Ziprasidone is approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia as well as acute mania and mixed states associated with bipolar disorder. Its intramuscular injection form is approved for acute agitation in schizophrenic patients for whom treatment with just ziprasidone is appropriate. [11]
In a 2013 study in a comparison of 15 antipsychotic drugs in effectiveness in treating schizophrenic symptoms, ziprasidone demonstrated mild-standard effectiveness. Ziprasidone was 15% more effective than lurasidone and iloperidone, approximately as effective as chlorpromazine and asenapine, and 9–13% less effective than haloperidol, quetiapine, and aripiprazole. [12] Ziprasidone is effective in the treatment of schizophrenia, though evidence from the CATIE trials suggests it is less effective than olanzapine, and equally as effective compared to quetiapine. There are higher discontinuation rates for lower doses of ziprasidone, which are also less effective than higher doses. [13]
Ziprasidone (and all other second generation antipsychotics (SGAs)) received a black box warning due to increased mortality in elderly patients with dementia-related psychosis. [14]
Sleepiness and headache are very common adverse effects (>10%). [6] [7]
Common adverse effects (1–10%), include producing too much saliva or having dry mouth, runny nose, respiratory disorders or coughing, nausea and vomiting, stomach aches, constipation or diarrhea, loss of appetite, weight gain (but the smallest risk for weight gain compared to other antipsychotics [8] ), rashes, fast heart beats, blood pressure falling when standing up quickly, muscle pain, weakness, twitches, dizziness, and anxiety. [6] [7] Extrapyramidal symptoms are also common and include tremor, dystonia (sustained or repetitive muscle contractions), akathisia (the feeling of a need to be in motion), parkinsonism, and muscle rigidity; in a 2013 meta-analysis of 15 antipsychotic drugs, ziprasidone ranked 8th for such side effects. [15]
Ziprasidone is known to trigger mania in some bipolar patients. [16] [17] [18]
This medication can cause birth defects, according to animal studies, although this side effect has not been confirmed in humans. [14]
Recently, the FDA required the manufacturers of some atypical antipsychotics to include a warning about the risk of hyperglycemia and Type II diabetes with atypical antipsychotics. Some evidence suggests that ziprasidone does not cause insulin resistance to the degree of other atypical antipsychotics, such as olanzapine. Weight gain is also less of a concern with ziprasidone compared to other atypical antipsychotics. [19] [20] [21] [22] In fact, in a trial of long term therapy with ziprasidone, overweight patients (BMI > 27) actually had a mean weight loss overall. [14] According to the manufacturer insert, ziprasidone caused an average weight gain of 2.2 kg (4.8 lbs), which is significantly lower than other atypical antipsychotics, making this medication better for patients that are concerned about their weight. In December 2014, the FDA warned that ziprasidone could cause a potentially fatal skin reaction, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), although this was believed to occur only rarely. [23]
The British National Formulary recommends a gradual withdrawal when discontinuing antipsychotics to avoid acute withdrawal syndrome or rapid relapse. [24] Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite. [25] Other symptoms may include restlessness, increased sweating, and trouble sleeping. [25] Less commonly there may be a feeling of the world spinning, numbness, or muscle pains. [25] Symptoms generally resolve after a short period of time. [25]
There is tentative evidence that discontinuation of antipsychotics can result in psychosis. [26] It may also result in reoccurrence of the condition that is being treated. [27] Rarely tardive dyskinesia can occur when the medication is stopped. [25]
Site | Ki (nM) | Action | Ref | |
---|---|---|---|---|
SERT | 112 | Blocker | [28] | |
NET | 44 | Blocker | [28] | |
DAT | >10,000 | ND | [28] | |
5-HT1A | 2.5–76 | Partial agonist | [29] [30] [31] | |
5-HT1B | 0.99–4.0 | Partial agonist | [30] [28] | |
5-HT1D | 5.1–9.0 | Partial agonist | [30] [28] | |
5-HT1E | 360–1,279 | ND | [30] [28] | |
5-HT2A | 0.08–1.4 | Antagonist | [32] [29] [30] | |
5-HT2B | 27.2 | Antagonist | [28] | |
5-HT2C | 0.72–13 | Antagonist | [29] | |
5-HT3 | >10,000 | ND | [28] | |
5-HT5A | 291 | ND | [28] | |
5-HT6 | 61–76 | Antagonist | [31] [29] | |
5-HT7 | 6.0–9.3 | Antagonist | [28] [31] [29] | |
α1A | 18 | Antagonist | [28] [31] | |
α1B | 9.0 | Antagonist | [28] | |
α2A | 160 | Antagonist | [28] [30] [31] | |
α2B | 48 | Antagonist | [28] [30] [31] | |
α2C | 59–77 | Antagonist | [28] [30] [31] | |
β1 | ≥2,570 | ND | [30] [28] | |
β2 | >10,000 | ND | [30] [28] | |
D1 | 30–130 | ND | [28] [29] | |
D2 | 4.8 | Antagonist | [33] [29] [31] | |
D2L | 4.6 | Antagonist | [30] [34] | |
D2S | 4.2 | Antagonist | [30] | |
D3 | 7.2 | Antagonist | [33] [29] [30] | |
D4 | 0.8–105 | Antagonist | [33] [29] [28] | |
D4.2 | 28–39 | Antagonist | [34] | |
D4.4 | 14.9 | Antagonist | [35] | |
D5 | 152 | ND | [28] | |
H1 | 15–130 | Antagonist | [30] [29] [28] | |
H2 | 3,500 | ND | [28] | |
H3 | >10,000 | ND | [28] | |
H4 | >10,000 | ND | [28] | |
M1 | ≥300 | ND | [36] [28] [29] | |
M2 | ≥3,000 | ND | [36] [28] | |
M3 | ≥1,300 | ND | [36] [31] [28] | |
M4 | ≥1,600 | ND | [36] [28] | |
M5 | ≥1,600 | ND | [36] [28] | |
σ1 | 110 | ND | [30] | |
σ2 | ND | ND | ND | |
Opioid | >1,000 | ND | [30] | |
nACh | >10,000 | ND | [28] | |
NMDA (PCP) | >10,000 | ND | [28] | |
VDCC | >10,000 | ND | [28] [30] | |
VGSC | 2,620 | ND | [30] | |
hERG | 169 | Blocker | [37] | |
Values are Ki (nM). The smaller the value, the more strongly the drug binds to the site. All data are for human cloned proteins, except H3 (guinea pig), σ1 (guinea pig), opioid (rodent), NMDA/PCP (rat), VDCC, and VGSC. [28] |
Ziprasidone mostly affects the receptors of dopamine (D2), serotonin (5-HT2A, partially 5-HT1A, 5-HT2C, and 5-HT1D) [3] [38] [39] and epinephrine/norepinephrine (α1) to a high degree, while of histamine (H1) - moderately. [40] [41] It also somewhat inhibits reuptake of serotonin and norepinephrine, though not dopamine. [40] [42]
Ziprasidone's efficacy in treating the positive symptoms of schizophrenia is believed to be mediated primarily via antagonism of the dopamine receptors, specifically D2. Blockade of the 5-HT2A receptor may also play a role in its effectiveness against positive symptoms, though the significance of this property in antipsychotic drugs is still debated among researchers. [43] Blockade of 5-HT2A and 5-HT2C and activation of 5-HT1A as well as inhibition of the reuptake of serotonin and norepinephrine may all contribute to its ability to alleviate negative symptoms. [44] ; however, its effects on the 5-HT1A receptor may be limited as a study [45] found ziprasidone would likely "produce detectable occupancy [of 5-HT1A receptors] only at higher doses that would produce unacceptable levels of side effects in man, although lower doses are sufficient to produce pharmacological effects." The relatively weak antagonistic actions of ziprasidone on the α1-adrenergic receptor likely in part explains some of its side effects, such as orthostatic hypotension. Unlike many other antipsychotics, ziprasidone has no significant affinity for the mACh receptors, and as such lacks any anticholinergic side effects. Like most other antipsychotics, ziprasidone is sedating due primarily to serotonin and dopamine blockade. [46] [47]
The systemic bioavailability of ziprasidone is 100% when administered intramuscularly and 60% when administered orally without food. [3]
After a single dose intramuscular administration, the peak serum concentration typically occurs at about 60 minutes after the dose is administered, or earlier. [48] Steady state plasma concentrations are achieved within one to three days. Exposure increases in a dose-related manner and following three days of intramuscular dosing, little accumulation is observed.
The bioavailability of the drug is reduced by approximately 50% if a meal is not eaten before Ziprasidone ingestion. [14] [49]
Ziprasidone is hepatically metabolized by aldehyde oxidase; minor metabolism occurs via cytochrome P450 3A4 (CYP3A4). [50] Medications that induce (e.g. carbamazepine) or inhibit (e.g. ketoconazole) CYP3A4 have been shown to decrease and increase, respectively, blood levels of ziprasidone. [51] [52]
Its biological half-life time is 10 hours at doses of 80–120 milligrams. [4]
Ziprasidone is chemically similar to risperidone, [53] of which it is a structural analogue. [54] It was first synthesized in 1987 at the Pfizer central research campus in Groton, Connecticut. [55]
Phase I trials started in 1995. [56] In 1998 ziprasidone was approved in Sweden. [57] [58] After the FDA raised concerns about long QT syndrome, more clinical trials were conducted and submitted to the FDA, which approved the drug on February 5, 2001. [56] [59] [60]
In September 2009, the U.S. Justice Department announced that Pfizer had been ordered to pay a historic fine of $2.3 billion as a penalty for fraudulent marketing of several drugs, including Geodon. [61] Pfizer had illegally promoted Geodon and submitted false claims to government health care programs for uses that were not medically accepted indications. The civil settlement also resolves allegations that Pfizer paid kickbacks to health care providers to induce them to prescribe Geodon, as well as other drugs. This was the largest civil fraud settlement in history against a pharmaceutical company.[ citation needed ]
Antipsychotics, previously known as neuroleptics and major tranquilizers, are a class of psychotropic medication primarily used to manage psychosis, principally in schizophrenia but also in a range of other psychotic disorders. They are also the mainstay, together with mood stabilizers, in the treatment of bipolar disorder. Moreover, they are also used as adjuncts in the treatment of treatment-resistant major depressive disorder.
Chlorpromazine (CPZ), marketed under the brand names Thorazine and Largactil among others, is an antipsychotic medication. It is primarily used to treat psychotic disorders such as schizophrenia. Other uses include the treatment of bipolar disorder, severe behavioral problems in children including those with attention deficit hyperactivity disorder, nausea and vomiting, anxiety before surgery, and hiccups that do not improve following other measures. It can be given orally, by intramuscular injection, or intravenously.
The atypical antipsychotics (AAP), also known as second generation antipsychotics (SGAs) and serotonin–dopamine antagonists (SDAs), are a group of antipsychotic drugs largely introduced after the 1970s and used to treat psychiatric conditions. Some atypical antipsychotics have received regulatory approval for schizophrenia, bipolar disorder, irritability in autism, and as an adjunct in major depressive disorder.
Risperidone, sold under the brand name Risperdal among others, is an atypical antipsychotic used to treat schizophrenia and bipolar disorder. It is taken either by mouth or by injection. The injectable versions are long-acting and last for 2–4 weeks.
Quetiapine, sold under the brand name Seroquel among others, is an atypical antipsychotic medication used for the treatment of schizophrenia, bipolar disorder, and major depressive disorder. Despite being widely used as a sleep aid due to its sedating effect, the benefits of such use may not outweigh its undesirable side effects. It is taken orally.
Olanzapine, sold under the brand name Zyprexa among others, is an atypical antipsychotic primarily used to treat schizophrenia and bipolar disorder. For schizophrenia, it can be used for both new-onset disease and long-term maintenance. It is taken by mouth or by injection into a muscle.
Aripiprazole, sold under the brand names Abilify and Aristada, among others, is an atypical antipsychotic. It is primarily used in the treatment of schizophrenia and bipolar disorder; other uses include as an add-on treatment in major depressive disorder and obsessive compulsive disorder (OCD), tic disorders, and irritability associated with autism. Aripiprazole is taken by mouth or via injection into a muscle. A Cochrane review found low-quality evidence of effectiveness in treating schizophrenia.
Azapirones are a class of drugs used as anxiolytics, antidepressants, and antipsychotics. They are commonly used as add-ons to other antidepressants, such as selective serotonin reuptake inhibitors (SSRIs).
A dopamine antagonist, also known as an anti-dopaminergic and a dopamine receptor antagonist (DRA), is a type of drug which blocks dopamine receptors by receptor antagonism. Most antipsychotics are dopamine antagonists, and as such they have found use in treating schizophrenia, bipolar disorder, and stimulant psychosis. Several other dopamine antagonists are antiemetics used in the treatment of nausea and vomiting.
Amisulpride is an antiemetic and antipsychotic medication used at lower doses intravenously to prevent and treat postoperative nausea and vomiting; and at higher doses by mouth to treat schizophrenia and acute psychotic episodes. It is sold under the brand names Barhemsys and Solian, Socian, Deniban and others. At very low doses it is also used to treat dysthymia.
Asenapine, sold under the brand name Saphris among others, is an atypical antipsychotic medication used to treat schizophrenia and acute mania associated with bipolar disorder as well as the medium to long-term management of bipolar disorder.
Iloperidone, commonly known as Fanapt and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia.
Perospirone (Lullan) is an atypical antipsychotic of the azapirone family. It was introduced in Japan by Dainippon Sumitomo Pharma in 2001 for the treatment of schizophrenia and acute cases of bipolar mania.
Blonanserin, sold under the brand name Lonasen, is a relatively new atypical antipsychotic commercialized by Dainippon Sumitomo Pharma in Japan and Korea for the treatment of schizophrenia. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension. As with many second-generation (atypical) antipsychotics it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics such as haloperidol.
Lurasidone, sold under the brand name Latuda among others, is an antipsychotic medication used to treat schizophrenia and bipolar disorder. It is taken by mouth.
Tiospirone (BMY-13,859), also sometimes called tiaspirone or tiosperone, is an atypical antipsychotic of the azapirone class. It was investigated as a treatment for schizophrenia in the late 1980s and was found to have an effectiveness equivalent to those of typical antipsychotics in clinical trials but without causing extrapyramidal side effects. However, development was halted and it was not marketed. Perospirone, another azapirone derivative with antipsychotic properties, was synthesized and assayed several years after tiospirone. It was found to be both more potent and more selective in comparison and was commercialized instead.
Cariprazine, sold under the brand names Vraylar, Reagila and Symvenu among others, is an atypical antipsychotic developed by Gedeon Richter, which is used in the treatment of schizophrenia, bipolar mania, bipolar depression, and major depressive disorder. It acts primarily as a D3 and D2 receptor partial agonist, with a preference for the D3 receptor. Cariprazine is also a partial agonist at the serotonin 5-HT1A receptor and acts as an antagonist at 5-HT2B and 5-HT2A receptors, with high selectivity for the D3 receptor. It is taken by mouth.
Brexpiprazole, sold under the brand name Rexulti among others, is a medication used for the treatment of major depressive disorder, schizophrenia, and agitation associated with dementia due to Alzheimer's disease. It is an atypical antipsychotic.
Brilaroxazine, also known as oxaripiprazole, is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of neuropsychiatric and inflammatory disorders. It has currently completed the first of two phase III clinical trials for schizophrenia. Reviva Pharmaceuticals also intends to investigate brilaroxazine for the treatment of bipolar disorder, major depressive disorder, attention deficit hyperactivity disorder (ADD/ADHD), psychosis/agitation associated with Alzheimer's disease, Parkinson's disease psychosis, as well as the inflammatory disorders pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF), and psoriasis. The FDA granted brilaroxazine orphan drug designation for the treatment of PAH and IPF.
Aripiprazole lauroxil, sold under the brand name Aristada, is a long-acting injectable atypical antipsychotic that was developed by Alkermes. It is an N-acyloxymethyl prodrug of aripiprazole that is administered via intramuscular injection once every four to eight weeks for the treatment of schizophrenia. Aripiprazole lauroxil was approved by the U.S. Food and Drug Administration (FDA) on 5 October 2015.
Withdrawal of antipsychotic drugs after long-term therapy should always be gradual and closely monitored to avoid the risk of acute withdrawal syndromes or rapid relapse.